Clinical Trial Search

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year

Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60

Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS) — -1.95…

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Endogenous Glucose Production — 0.5; 0.84; 0.6; 0.4 mg/kg/min

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032

Primary: Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6% — 4; 4 Participants

Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05

Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05

Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants

Primary: Count of Participants Who Completed the Study — 28; 33 Participants

Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants

Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01

Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…

Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin

Primary: Weight — 103.8; 100.7 kg — p=0.44

Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants

Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12 — 50; 4; 50; 26 Participants

Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl

Primary: Change in Hemoglobin A1c From Baseline to Week 12 — 6.6; 7.2 percentage

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 — 0.0005; 0.0029; 0.0007; 0.0004 Percent Change